Cargando…

“Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations

BACKGROUND: According to the AMNOG act, the German Federal Joint Committee (G-BA) determines the additional benefit of new medicines as a basis for subsequent price negotiations. Pharmaceutical companies may withdraw their medications from the market at any time during the process. This analysis aim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Staab, Thomas R., Walter, Miriam, Mariotti Nesurini, Sonja, Dintsios, Charalabos-Markos, Graf von der Schulenburg, J.-Matthias, Amelung, Volker E., Ruof, Jörg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755547/ https://www.ncbi.nlm.nih.gov/pubmed/30229501 http://dx.doi.org/10.1186/s13561-018-0209-3

Ejemplares similares

Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation
por: Ruof, Jörg, et al.
Publicado: (2013)

Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany – are additional data requirements by the Federal Joint Committee justified?
por: Ruof, Jörg, et al.
Publicado: (2016)

How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?
por: Dintsios, Charalabos-Markos, et al.
Publicado: (2021)

The impact of HTA reports on health policy: a systematic review
por: Gerhardus, Ansgar, et al.
Publicado: (2005)

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree
por: Dintsios, C. M., et al.
Publicado: (2019)

Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany
por: Dabisch, Inna, et al.
Publicado: (2014)

Leveraging EUnetHTA’s conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer’s point of view
por: Giuliani, Giovanni, et al.
Publicado: (2018)

Predictors of negotiated prices for new drugs in Germany
por: Gandjour, Afschin, et al.
Publicado: (2020)

10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
por: Büssgen, Melanie, et al.
Publicado: (2023)

Implementation of AMNOG: An industry perspective
por: Leverkus, Friedhelm, et al.
Publicado: (2015)

Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases
por: Staab, Thomas, et al.
Publicado: (2016)

Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment
por: Gandjour, Afschin
Publicado: (2023)

Coated stents to prevent restenosis in coronary heart disease
por: Gorenoi, Vitali, et al.
Publicado: (2005)

Quantified patient preferences for lifestyle intervention programs for diabetes prevention—a protocol for a systematic review
por: Dintsios, Charalabos-Markos, et al.
Publicado: (2018)

Drug-eluting stents vs. coronary artery bypass-grafting in coronary heart disease
por: Gorenoi, Vitali, et al.
Publicado: (2008)

Intravascular brachytherapy for peripheral vascular disease
por: Gorenoi, Vitali, et al.
Publicado: (2008)

Laparoscopic vs. open appendectomy: systematic review of medical efficacy and health economic analysis
por: Gorenoi, Vitali, et al.
Publicado: (2007)

Real world data in health technology assessments in kidney transplants in Germany: use of routinely collected data to address epidemiologic questions in kidney transplants in the AMNOG process in Germany
por: Herrmann, Kirsten H., et al.
Publicado: (2018)

Relevance of Variations in the Opposing Dentition for the Functionality of Fixed and Removable Partial Dentures: A Systematic Review
por: Pommer, Bernhard, et al.
Publicado: (2012)

Promoting physical activity in low back pain patients: six months follow-up of a randomised controlled trial comparing a multicomponent intervention with a low intensity intervention
por: Schaller, Andrea, et al.
Publicado: (2016)

Ten years of AMNOG from an oncological perspective: new horizons and continuing expansion
por: Bartol, Arne, et al.
Publicado: (2022)

Towards compatibility of EUnetHTA JCA methodology and German HTA: a systematic comparison and recommendations from an industry perspective
por: Kisser, Agnes, et al.
Publicado: (2021)

Krebsforschung in Deutschland zwischen AMNOG, CTIS und digitalen Datenräumen: An der Schnittstelle zur Zukunft
por: Grätzel von Grätz, Philipp
Publicado: (2023)

Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
por: Ruof, Jörg, et al.
Publicado: (2015)

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
por: Kawalec, Paweł, et al.
Publicado: (2016)

External validation of type 2 diabetes computer simulation models: definitions, approaches, implications and room for improvement—a protocol for a systematic review
por: Ogurtsova, Katherine, et al.
Publicado: (2017)

Zehn Jahre AMNOG-Prozess aus Sicht der Onkologie: Neuland erschlossen, Bebauung geht weiter
por: Bartol, Arne, et al.
Publicado: (2022)

Expanding HTA – Correcting a Misattribution, Clarifying the Scope of HTA and CEA: Comment on "Ethics in HTA: Examining the ‘Need for Expansion’"
por: Culyer, Anthony J.
Publicado: (2019)

Benefit assessment in Germany: implications for price discounts
por: Theidel, Ulrike, et al.
Publicado: (2016)

Navigating HTA implementation: a review of Indonesia’s revised HTA guideline
por: Chavarina, Kinanti Khansa, et al.
Publicado: (2023)

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
por: Allen, Nicola, et al.
Publicado: (2017)

GMS-HTA: Information out of the world of HTA - up-to-date, comprehensive and valid
por: Rüther, Alric
Publicado: (2005)

From recommendation to action: psychosocial factors influencing physician intention to use Health Technology Assessment (HTA) recommendations
por: Gagnon, Marie-Pierre, et al.
Publicado: (2006)

Recommendations for the Implementation of Hospital Based HTA in Poland: Lessons Learned From International Experience
por: Gałązka-Sobotka, Małgorzata, et al.
Publicado: (2021)

HTA Training for Healthcare Professionals: International Overview of Initiatives Provided by HTA Agencies and Organizations
por: Hoxhaj, Ilda, et al.
Publicado: (2022)

Implementation of a multicomponent intervention to prevent physical restraints in nursing home residents (IMPRINT): study protocol for a cluster-randomised controlled trial
por: Abraham, Jens, et al.
Publicado: (2015)

The Impact of Brexit on Pharmaceuticals and HTA
por: Lorgelly, Paula K
Publicado: (2018)

Perspektiven der molekulargenetischen Therapien: Zur Notwendigkeit der Weiterentwicklung des AMNOG Bewertungssystems im Bereich der personalisierten Medizin
por: Woskowski, Silvia, et al.
Publicado: (2022)

Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges
por: Daubner-Bendes, Rita, et al.
Publicado: (2021)

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines
por: Lach, Krzysztof, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_59numd55c3qlsv6t40ft2vmm1p